Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LyRICX: Liposomal iRInotecan, Carboplatin or oXaliplatin in First Line Treatment of Esophagogastric Cancer
NCT03764553Phase 2Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- May 2019
- Primary completion
- Jul 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in Esophagogastric Cancer, sponsored by University of Amsterdam. Started May 2019; status: active, not recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
Esophagogastric Cancer
Beyond the preview
Go deeper on NCT03764553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764553.